Onconova Therapeutics (NASDAQ:ONTX) is up 17% premarket on robust volume in reaction to its announcement that
it has regained the rights to rigosertib in Greater China subsequent to
the termination of its license agreement with HanX Biopharmaceuticals
after the latter failed to make required payments.
https://seekingalpha.com/news/3533936-onconova-regains-rigosertib-rights-in-china-shares-up-17-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.